ARTICLES
mixture was stirred at 278 8C for 2 h then gradually warmed to room temperature
and stirred for a further 16 h, then quenched with water and diluted with
dichloromethane (100 ml). The combined organics were washed with saturated
aqueous NaHCO3 (50 ml) and brine (50 ml), dried (Na2SO4) and concentrated. The
crude product was purified by chromatography (silica gel 100% ethyl acetate) to
afford lactam 19 (800 mg, 45%) as a light yellow oil.
27. Costantino, L. & Barlocco, D. Privileged structures as leads in medicinal
chemistry. Front. Med. Chem. 5, 381–422 (2010).
28. Verma, A. et al. Nitrogen-containing privileged structures and their solid phase
combinatorial synthesis. Comb. Chem. High T. Scr. 16, 345–393 (2013).
29. Frankowski, K. J. et al. Synthesis and receptor profiling of Stemona alkaloid
analogues reveal a potent class of sigma ligands. Proc. Natl Acad. Sci. USA
108, 6727–6732 (2011).
30. Pilli, R. A., Rosso, G. B. & de Oliveira, M. d. C. F. The Stemona alkaloids.
Alkaloids 62, 77–173 (2005).
Received 22 July 2013; accepted 5 December 2013;
published online 19 January 2014
31. Pilli, R. A., Rosso, G. B. & de Oliveira, M. d. C. F. The chemistry of Stemona
alkaloids: an update. Nat. Prod. Rep. 27, 1908–1937 (2010).
32. Weinreb, S. M. Studies on total synthesis of the cylindricine/fasicularin/
lepadiformine family of tricyclic marine alkaloids. Chem. Rev. 106,
2531–2549 (2006).
33. Gericke, N. & Viljoen, A. M. Sceletium—a review update. J. Ethnopharm.
119, 653–663 (2008).
34. Perez, E. G., Mendez-Galvez, C. & Cassels, B. K. Cytisine: a natural product lead
for the development of drugs acting at nicotinic acetylcholine receptors. Nat.
Prod. Rep. 29, 555–567 (2012).
References
1. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the
last 25 years. J. Nat. Prod. 70, 461–477 (2007).
2. Butler, M. S. Natural products to drugs: natural product-derived compounds in
clinical trials. Nat. Prod. Rep. 25, 475–516 (2008).
3. Paterson, I. & Anderson, E. A. Chemistry. The renaissance of natural products as
drug candidates. Science 310, 451–453 (2005).
4. Ganesan, A. The impact of natural products upon modern drug discovery. Curr.
Opin. Chem. Biol. 12, 306–317 (2008).
5. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).
6. Boldi, A. M. Libraries from natural product-like scaffolds. Curr. Opin. Chem.
Biol. 8, 281–286 (2004).
35. Daly, J. W. Nicotinic agonists, antagonists, and modulators from natural sources.
Cell. Mol. Neurobiol. 25, 513–552 (2005).
´
36. Wrobleski, A., Coombs, T. C., Huh, C. W., Li, S-W. & Aube, J. The Schmidt
reaction. Org. React. 78, 1–320 (2012).
37. Zeng, Y., Reddy, D. S., Hirt, E. & Aube, J. Domino reactions that combine an
azido–Schmidt ring expansion with the Diels–Alder reaction. Org. Lett. 6,
4993–4995 (2004).
7. Thomas, G. L. & Johannes, C. W. Natural product-like synthetic libraries. Curr.
Opin. Chem. Biol. 15, 516–522 (2011).
´
38. Gracias, V., Frank, K. E., Milligan, G. L. & Aube, J. Ring expansion by in situ
tethering of hydroxy azides to ketones: the Boyer reaction. Tetrahedron 53,
16241–16252 (1997).
8. Camp, D., Davis, R. A., Evans-Illidge, E. A. & Quinn, R. J. Guiding principles for
natural product drug discovery. Future Med. Chem. 4, 1067–1084 (2012).
9. Lachance, H., Wetzel, S., Kumar, K. & Waldmann, H. Charting, navigating, and
populating natural product chemical space for drug discovery. J. Med. Chem. 55,
5989–6001 (2012).
10. Zuegg, J. & Cooper, M. A. Drug-likeness and increased hydrophobicity of
commercially available compound libraries for drug screening. Curr. Top. Med.
Chem. 12, 1500–1513 (2012).
11. Njardarson, J. T., Gaul, C., Shan, D., Huang, X-Y. & Danishefsky, S. J. Discovery
of potent cell migration inhibitors through total synthesis: lessons from
structure–activity studies of (þ)-migrastatin. J. Am. Chem. Soc. 126,
1038–1040 (2004).
12. Szpilman, A. M. & Carreira, E. M. Probing the biology of natural products.
Molecular editing by diverted total synthesis. Angew. Chem. Int. Ed. 49,
9592–9628 (2010).
13. Wetzel, S., Bon, R. S., Kumar, K. & Waldmann, H. Biology-oriented synthesis.
Angew. Chem. Int. Ed. 50, 10800–10826 (2011).
14. Burke, M. D. & Schreiber, S. L. A planning strategy for diversity-oriented
synthesis. Angew. Chem. Int. Ed. 43, 46–58 (2004).
15. Huigens, R. W. et al. A ring-distortion strategy to construct stereochemically
complex and structurally diverse compounds from natural products. Nature
Chem. 5, 195–202 (2013).
16. Kim, Y. K. et al. Relationship of stereochemical and skeletal diversity of small
molecules to cellular measurement space. J. Am. Chem. Soc. 126,
14740–14745 (2004).
39. Smith, B. T., Wendt, J. A. & Aube, J. First asymmetric total synthesis of (þ)-
sparteine. Org. Lett. 4, 2577–2579 (2002).
40. Meyer, A. M., Katz, C. E., Li, S-W., Vander Velde, D. & Aube?, J. A tandem
Prins/Schmidt reaction approach to marine alkaloids: formal and total syntheses
of lepadiformines A and C. Org. Lett. 12, 1244–1247 (2010).
41. Fenster, E. et al. Three-component synthesis of 1,4-diazepin-5-ones and the
construction of g-turn-like peptidomimetic libraries. J. Comb. Chem. 10,
230–234 (2008).
42. Trost, B. M. & Bogdanowicz, M. J. New synthetic reactions. X. Versatile
cyclobutanone (spiroannelation) and g-butyrolactone (lactone annelation)
synthesis. J. Am. Chem. Soc. 95, 5321–5334 (1973).
43. Li, X. & Danishefsky, S. J. Cyclobutenone as a highly reactive dienophile:
expanding upon Diels–Alder paradigms. J. Am. Chem. Soc. 132,
11004–11005 (2010).
44. Xue, L., Stahura, F. & Bajorath, J. in Chemoinformatics Vol. 275 (ed. Ju¨rgen
Bajorath) Ch. 9, 279–289 (Humana, 2004).
45. Kopp, F., Stratton, C. F., Akella, L. B. & Tan, D. S. A diversity-oriented
synthesis approach to macrocycles via oxidative ring expansion. Nature Chem.
Biol. 8, 358–365 (2012).
46. Sauer, W. H. B. & Schwarz, M. K. Molecular shape diversity of combinatorial
libraries: a prerequisite for broad bioactivity. J. Chem. Inf. Comput. Sci.
43, 987–1003 (2003).
47. Veber, D. F. et al. Molecular properties that influence the oral bioavailability of
drug candidates. J. Med. Chem. 45, 2615–2623 (2002).
48. Bauer, R. A., Wurst, J. M. & Tan, D. S. Expanding the range of ‘druggable’ targets
with natural product-based libraries: an academic perspective. Curr. Opin.
Chem. Biol. 14, 308–314 (2010).
17. Shelat, A. A. & Guy, R. K. Scaffold composition and biological relevance of
screening libraries. Nature Chem. Biol. 3, 442–446 (2007).
18. Lovering, F., Bikker, J. & Humblet, C. Escape from flatland: increasing saturation
as an approach to improving clinical success. J. Med. Chem. 52,
6752–6756 (2009).
19. Clemons, P. A. et al. Quantifying structure and performance diversity for sets of
small molecules comprising small-molecule screening collections. Proc. Natl
Acad. Sci. USA 108, 6817–6822 (2011).
Acknowledgements
The authors thank P. Porubsky and B. Neuenswander for purification of library
compounds. The authors also acknowledge financial support from the US Institute of
General Medical Sciences (P41 GM089164, Pilot-scale Libraries Initiative;
5P50GM069663, KU Chemical Methodologies and Library Development Center) and an
NSF-MRI grant (CHE-0923449) for the purchase of an X-ray diffractometer.
20. Lovering, F. Escape from flatland 2: complexity and promiscuity.
MedChemComm 4, 515–519 (2013).
21. Nandy, J. P. et al. Advances in solution- and solid-phase synthesis toward the
generation of natural product-like libraries. Chem. Rev. 109, 1999–2060 (2009).
22. MacLellan, P. & Nelson, A. A conceptual framework for analysing and planning
synthetic approaches to diverse lead-like scaffolds. Chem. Commun. 49,
2383–2393 (2013).
23. Evans, B. E. et al. Methods for drug discovery: development of potent, selective,
orally effective cholecystokinin antagonists. J. Med. Chem. 31,
2235–2246 (1988).
Author contributions
M.C.M., J.N.P., D.R., G.S. and J.A. designed the experiments and analysed the data. M.C.M.,
J.N.P., D.R. and G.S. performed the synthesis and characterization. J.L.W. and M.C.M.
performed the cheminformatic analysis and V.W.D. performed and analysed the X-ray
structures. M.C.M. and J.A. wrote the manuscript.
Additional information
24. DeSimone, R. W., Currie, K. S., Mitchell, S. A., Darrow, J. W. & Pippin, D. A.
Privileged structures: applications in drug discovery. Comb. Chem. High T. Scr. 7,
473–493 (2004).
25. Costantino, L. & Barlocco, D. Privileged structures as leads in medicinal
chemistry. Curr. Med. Chem. 13, 65–85 (2006).
Supplementary information and chemical compound information are available in
the online version of the paper. Reprints and permissions information is available online at
addressed to J.A.
26. Duarte, C. D., Barreiro, E. J. & Fraga, C. A. M. Privileged structures: a
useful concept for the rational design of new lead drug candidates. Mini-Rev.
Med. Chem. 7, 1108–1119 (2007).
Competing financial interests
The authors declare no competing financial interests.
140
© 2014 Macmillan Publishers Limited. All rights reserved.